{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:52:42Z","timestamp":1777711962197,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.4065\/mcp.2010.0346","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T01:12:19Z","timestamp":1284599539000},"page":"913-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Low Allergenic Potential With Fondaparinux: Results of a Prospective Investigation"],"prefix":"10.4065","volume":"85","author":[{"given":"Marc","family":"Schindewolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurate","family":"Garbaraviciene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6319, suppl","key":"10.4065\/mcp.2010.0346_bib1","first-page":"30","article-title":"Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs","volume":"350","author":"Petitou","year":"1991","journal-title":"Nature"},{"issue":"6, suppl","key":"10.4065\/mcp.2010.0346_bib2","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"issue":"6, suppl","key":"10.4065\/mcp.2010.0346_bib3","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Harrington","year":"2008","journal-title":"Chest"},{"issue":"5","key":"10.4065\/mcp.2010.0346_bib4","first-page":"611","article-title":"Management of cutaneous type IV hypersensitivity reactions induced by heparin","volume":"96","author":"Ludwig","year":"2006","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.4065\/mcp.2010.0346_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2009.04.006","article-title":"Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection","volume":"29","author":"Trautmann","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"issue":"27","key":"10.4065\/mcp.2010.0346_bib6","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.2174\/138161208786369768","article-title":"Hypersensitivity reactions to anticoagulant drugs","volume":"14","author":"Scherer","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"8","key":"10.4065\/mcp.2010.0346_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1503\/cmaj.081729","article-title":"Incidence and causes of heparin-induced skin lesions","volume":"181","author":"Schindewolf","year":"2009","journal-title":"CMAJ"},{"issue":"6","key":"10.4065\/mcp.2010.0346_bib8","first-page":"1265","article-title":"Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides","volume":"94","author":"Ludwig","year":"2005","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.4065\/mcp.2010.0346_bib9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1468-3083.2007.02333.x","article-title":"Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin","volume":"22","author":"Schindewolf","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.4065\/mcp.2010.0346_bib10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1046\/j.1398-9995.2003.00292.x","article-title":"Tolerance to the synthetic pentasaccharide fondaparinux in heparin sensitization","volume":"58","author":"Sacher","year":"2003","journal-title":"Allergy"},{"issue":"6","key":"10.4065\/mcp.2010.0346_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.0105-1873.2004.0350j.x","article-title":"Intolerance of fondaparinux in a patient allergic to heparins","volume":"50","author":"Hirsch","year":"2004","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.4065\/mcp.2010.0346_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1160\/TH05-04-0895","article-title":"Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy","volume":"94","author":"Utikal","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.4065\/mcp.2010.0346_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2141.1996.d01-1481.x","article-title":"Heparin-induced skin lesions","volume":"92","author":"Warkentin","year":"1996","journal-title":"Br J Haematol"},{"issue":"5","key":"10.4065\/mcp.2010.0346_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1034\/j.1398-9995.1999.00048.x","article-title":"Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG","volume":"54","author":"Harenberg","year":"1999","journal-title":"Allergy"},{"issue":"1","key":"10.4065\/mcp.2010.0346_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI116987","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells","volume":"93","author":"Visentin","year":"1994","journal-title":"J Clin Invest"},{"issue":"8","key":"10.4065\/mcp.2010.0346_bib16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1538-7836.2009.03465.x","article-title":"Prospective evaluation of PF4\/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia","volume":"7","author":"Bakchoul","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"8961","key":"10.4065\/mcp.2010.0346_bib17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(95)92535-X","article-title":"Accuracy of clinical assessment of deep-vein thrombosis","volume":"345","author":"Wells","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.4065\/mcp.2010.0346_bib18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.4065\/mcp.2010.0346_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0037-1622313","article-title":"Diagnosis of heparin-induced delayed type hypersensitivity","volume":"39","author":"Schindewolf","year":"2010","journal-title":"Phlebologie"},{"issue":"1, suppl","key":"10.4065\/mcp.2010.0346_bib20","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"12","key":"10.4065\/mcp.2010.0346_bib21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/anie.199316713","article-title":"The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics","volume":"32","author":"van Boeckel","year":"1993","journal-title":"Angew Chem Int Ed Engl"},{"issue":"24","key":"10.4065\/mcp.2010.0346_bib22","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1002\/anie.200300640","article-title":"A synthetic antithrombin III binding pentasaccharide is now a drug! what comes next?","volume":"43","author":"Petitou","year":"2004","journal-title":"Angew Chem Int Ed Engl"},{"issue":"suppl 2","key":"10.4065\/mcp.2010.0346_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003088-200241002-00002","article-title":"Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins","volume":"41","author":"Paolucci","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.4065\/mcp.2010.0346_bib24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1055\/s-0038-1649842","article-title":"Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia","volume":"74","author":"Greinacher","year":"1995","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.4065\/mcp.2010.0346_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2007.08402.x","article-title":"The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; [in response to Grims et al, Br J Dermatol 2007;157:514-17.]","volume":"158","author":"Ludwig","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.4065\/mcp.2010.0346_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-1873.2004.00399.x","article-title":"Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? a study of 7 cases","volume":"51","author":"Jappe","year":"2004","journal-title":"Contact Dermatitis"},{"issue":"1","key":"10.4065\/mcp.2010.0346_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","article-title":"Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia","volume":"105","author":"Rauova","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.4065\/mcp.2010.0346_bib28","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.ATV.0000238350.89477.88","article-title":"Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies","volume":"26","author":"Greinacher","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.4065\/mcp.2010.0346_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1046\/j.1538-7836.2003.t01-7-00115.x","article-title":"High rate of skin complications due to low-molecular-weight heparins in pregnant women","volume":"1","author":"Bank","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.4065\/mcp.2010.0346_bib30","first-page":"89","article-title":"Danaparoid in pregnancy in cases of heparin intolerance\u2014use in 59 cases [in German]","volume":"27","author":"Schindewolf","year":"2007","journal-title":"Hamostaseologie"},{"issue":"18","key":"10.4065\/mcp.2010.0346_bib31","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1056\/NEJM200404293501825","article-title":"Minor transplacental passage of fondaparinux in vivo","volume":"350","author":"Dempfle","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.4065\/mcp.2010.0346_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH05-07-0515","article-title":"The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo","volume":"95","author":"Ludwig","year":"2006","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.4065\/mcp.2010.0346_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-0536.1996.tb02293.x","article-title":"Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids","volume":"35","author":"Boehncke","year":"1996","journal-title":"Contact Dermatitis"},{"issue":"2","key":"10.4065\/mcp.2010.0346_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/bjs.4809","article-title":"Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro","volume":"92","author":"Handschin","year":"2005","journal-title":"Br J Surg"},{"issue":"1","key":"10.4065\/mcp.2010.0346_bib35","first-page":"168","article-title":"Fondaparinux-related thrombocytopenia in a patient with former HIT. [Response to Rota, et al. (Thromb Haemost 2008;99:779-781) letter reply]","volume":"100","author":"Schindewolf","year":"2008","journal-title":"Thromb Haemost"},{"issue":"25","key":"10.4065\/mcp.2010.0346_bib36","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611602322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611602322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T14:24:38Z","timestamp":1675866278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611602322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0025619611602322"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2010.0346","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Allergenic Potential With Fondaparinux: Results of a Prospective Investigation","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}